TRITON-PN : Étude visant à évaluer l'efficacité et l'innocuité du nucrésiran chez les patients atteints d'amylose héréditaire à transthyrétine avec polyneuropathie (TRITON-PN)
TRITON-PN : Une étude de phase 3, mondiale, randomisée, ouverte évaluant l'efficacité et l'innocuité du nucresiran chez les patients atteints d'amylose héréditaire à transthyrétine avec polyneuropathie (hATTR-PN)
The purpose of this study is to:
- Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed
- Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Clinical Trial Information Line
- Numéro de téléphone: 1-877-ALNYLAM
- E-mail: clinicaltrials@alnylam.com
Sauvegarde des contacts de l'étude
- Nom: Clinical Trial Information Line
- Numéro de téléphone: 1-877-256-9526
- E-mail: clinicaltrials@alnylam.com
Lieux d'étude
-
-
-
Berlin, Allemagne, 10117
- Recrutement
- Clinical Trial Site
-
Heidelberg, Allemagne, 69120
- Recrutement
- Clinical Trial Site
-
Münster, Allemagne, 48149
- Recrutement
- Clinical Trial Site
-
-
-
-
-
Belgrano, Argentine, C1428AQK
- Recrutement
- Clinical Trial Site
-
Rosario, Argentine, CP2000
- Recrutement
- Clinical Trial Site
-
-
-
-
-
Darlinghurst, Australie, 2010
- Recrutement
- Clinical Trial Site
-
Woolloongabba, Australie, 4102
- Recrutement
- Clinical Trial Site
-
-
-
-
-
Ribeirão Preto, Brésil, 14051-140
- Recrutement
- Clinical Trial Site
-
Rio de Janeiro, Brésil, 22640-100
- Recrutement
- Clinical Trial Site
-
Rio de Janeiro, Brésil, 22775-001
- Recrutement
- Clinical Trial Site
-
Salvador, Brésil, 40290-000
- Recrutement
- Clinical Trial Site
-
São Paulo, Brésil, 04038-002
- Recrutement
- Clinical Trial Site
-
-
-
-
-
Vancouver, Canada, V5Z 1M9
- Recrutement
- Clinical Trial Site
-
-
-
-
-
Égkomi, Chypre, 2371
- Recrutement
- Clinical Trial Site
-
-
-
-
-
Seoul, Corée du Sud, 06351
- Recrutement
- Clinical Trial Site
-
Seoul, Corée du Sud, 05030
- Recrutement
- Clinical Trial Site
-
-
-
-
-
Barcelona, Espagne, 08035
- Recrutement
- Clinical Trial Site
-
Huelva, Espagne, 21005
- Recrutement
- Clinical Trial Site
-
L'Hospitalet de Llobregat, Espagne, 8907
- Recrutement
- Clinical Trial Site
-
Madrid, Espagne, 28040
- Recrutement
- Clinical Trial Site
-
Palma de Mallorca, Espagne, 07198
- Recrutement
- Clinical Trial Site
-
-
-
-
-
Créteil, France, 94000
- Recrutement
- Clinical Trial Site
-
Le Kremlin-Bicêtre, France, 94270
- Recrutement
- Clinical Trial Site
-
Marseille, France, 13005
- Recrutement
- Clinical Trial Site
-
-
-
-
-
Athens, Grèce, 115 28
- Recrutement
- Clinical Trial Site
-
Heraklion, Grèce, 715 00
- Recrutement
- Clinical Trial Site
-
-
-
-
-
Dublin, Irlande, D24 NR0A
- Recrutement
- Clinical Trial Site
-
-
-
-
-
Florence, Italie, 50134
- Recrutement
- Clinical Trial Site
-
Milan, Italie, 20133
- Recrutement
- Clinical Trial Site
-
Padova, Italie, 35128
- Recrutement
- Clinical Trial Site
-
Pavia, Italie, 27100
- Recrutement
- Clinical Trial Site
-
Roma, Italie, 00168
- Recrutement
- Clinical Trial Site
-
-
-
-
-
Bunkyo C, Japon, 113-8519
- Recrutement
- Clinical Trial Site
-
Kumamoto, Japon, 860-8556
- Recrutement
- Clinical Trial Site
-
Matsumoto-shi, Japon, 390-8621
- Recrutement
- Clinical Trial Site
-
Suita, Japon, 565-0871
- Recrutement
- Clinical Trial Site
-
-
-
-
-
Lisbon, Le Portugal, 1649-035
- Recrutement
- Clinical Trial Site
-
Porto, Le Portugal, 4099-001
- Recrutement
- Clinical Trial Site
-
-
-
-
-
Kuala Lumpur, Malaisie, 59100
- Recrutement
- Clinical Trial Site
-
-
-
-
-
Guadalajara, Mexique, 44670
- Recrutement
- Clinical Trial Site
-
Tlalpan, Mexique, 14080
- Recrutement
- Clinical Trial Site
-
-
-
-
-
London, Royaume-Uni, NW3 2QG
- Recrutement
- Clinical Trial Site
-
-
-
-
-
Bern, Suisse, 3010
- Recrutement
- Clinical Trial Site
-
-
-
-
-
Stockholm, Suède, 113 61
- Recrutement
- Clinical Trial Site
-
Umeå, Suède, 907 37
- Recrutement
- Clinical Trial Site
-
-
-
-
-
Taipei, Taïwan, 10002
- Recrutement
- Clinical Trial Site
-
Taipei, Taïwan, 112
- Recrutement
- Clinical Trial Site
-
Taoyuan City, Taïwan, 33305
- Recrutement
- Clinical Trial Site
-
-
-
-
-
Istanbul, Turquie (Türkiye), 34093
- Recrutement
- Clinical Trial Site
-
Izmir, Turquie (Türkiye), 35330
- Recrutement
- Clinical Trial Site
-
-
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- Recrutement
- Clinical Trial Site
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Recrutement
- Clinical Trial Site
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21287
- Recrutement
- Clinical Trial Site
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02118
- Recrutement
- Clinical Trial Site
-
-
Minnesota
-
Rochester, Minnesota, États-Unis, 55905
- Recrutement
- Clinical Trial Site
-
-
New York
-
New York, New York, États-Unis, 10032
- Recrutement
- Clinical Trial Site
-
New York, New York, États-Unis, 10016
- Recrutement
- Clinical Trial Site
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27514
- Recrutement
- Clinical Trial Site
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37232
- Recrutement
- Clinical Trial Site
-
-
Texas
-
Dallas, Texas, États-Unis, 75246
- Recrutement
- Clinical Trial Site
-
Houston, Texas, États-Unis, 77030
- Recrutement
- Clinical Trial Site
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Has documented diagnosis of hATTR-PN
- Has a diagnosis of hATTR amyloidosis with polyneuropathy with a documented TTR gene variant
- Has a neuropathy impairment score (NIS) of 5 to 130 (inclusive)
- Has a Karnofsky Performance Status (KPS) of ≥60%
Exclusion Criteria:
- Has had a liver transplant or is likely, in the opinion of the Investigator, to undergo liver transplantation during the Treatment Period of the study
- Has known other (non-hATTR) forms of amyloidosis or clinical evidence of leptomeningeal amyloidosis
- Has a New York Heart Association (NYHA) heart failure classification >2
- Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 upper limit of normal (ULN)
- Has total bilirubin >1.5 ULN
- Has estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73m^2
- Has other known causes of sensorimotor or autonomic neuropathy
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Nucresiran 300 mg
Patients will be administered nucresiran 300 mg subcutaneously (SC) once every 6 months (q6M) during the Treatment Period and Treatment Extension Period |
Nucresiran 300 mg administered SC q6M
Autres noms:
|
|
Comparateur actif: Vutrisiran 25 mg followed by Nucresiran 300 mg
Patients will be administered vutrisiran 25 mg SC every 3 months (q3M) during the Treatment Period followed by nucresiran 300 mg SC q6M during the Treatment Extension Period |
Nucresiran 300 mg administered SC q6M
Autres noms:
Vutrisiran 25 mg administered SC q3M
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from Baseline in the Modified Neuropathy Impairment Score +7 (mNIS+7) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Délai: Baseline and Month 9
|
The mNIS+7 is a composite score that measures neurologic impairment which includes the following components: physical exam of lower limbs, upper limbs and cranial nerves to assess motor strength/weakness and deep tendon reflexes, electrophysiologic measurement of large nerve fiber function, sensory testing and postural blood pressure. The mNIS+7 is scored from 0 (no impairment) to 304 points (maximum impairment). A higher score indicates a worse outcome. |
Baseline and Month 9
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Pourcentage de réduction des taux sériques de TTR dans le groupe Nucresiran par rapport au groupe Vutrisiran dans l'étude jusqu'au mois 9
Délai: Jusqu'au mois 9
|
Jusqu'au mois 9
|
|
|
Pourcentage de réduction des taux sériques de TTR dans le groupe nucresiran par rapport au groupe vutrisiran de l'étude jusqu'au 18e mois
Délai: Jusqu'à 18 mois
|
Jusqu'à 18 mois
|
|
|
Réduction en pourcentage des taux sériques de TTR dans le groupe Nucresiran par rapport au groupe Vutrisiran de l'étude à la semaine 6
Délai: Semaine 6
|
Semaine 6
|
|
|
Change from Baseline in Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) Total Score Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Délai: Baseline and Month 9
|
The Norfolk QoL-DN is a standardized 35-item patient-rated questionnaire used to assess 5 domains: physical function, large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome. |
Baseline and Month 9
|
|
Change from Baseline in Modified Body Mass Index (mBMI) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Délai: Baseline and Month 9
|
The mBMI, which is a measure of nutritional status, is calculated as the product of body mass index (BMI) (weight in kilograms divided by the square of height in meters) and serum albumin (g/L) to reflect fluid balance, such as fluid accumulation or dehydration. A negative change from baseline indicates a better outcome. |
Baseline and Month 9
|
|
Change from Baseline in the mNIS+7 Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Délai: Baseline and Month 18
|
The mNIS+7 is a composite score that measures neurologic impairment which includes the following components: physical exam of lower limbs, upper limbs and cranial nerves to assess motor strength/weakness and deep tendon reflexes, electrophysiologic measurement of large nerve fiber function, sensory testing and postural blood pressure. The mNIS+7 is scored from 0 (no impairment) to 304 points (maximum impairment). A higher score indicates a worse outcome. |
Baseline and Month 18
|
|
Change from Baseline in Norfolk QoL-DN Total Score Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Délai: Baseline and Month 18
|
The Norfolk QoL-DN is a standardized 35-item patient-rated questionnaire used to assess 5 domains: physical function, large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome. |
Baseline and Month 18
|
|
Change from Baseline in mBMI Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Délai: Baseline and Month 18
|
The mBMI, which is a measure of nutritional status, is calculated as the product of body mass index (BMI) (weight in kilograms divided by the square of height in meters) and serum albumin (g/L) to reflect fluid balance, such as fluid accumulation or dehydration. A negative change from baseline indicates a better outcome. |
Baseline and Month 18
|
|
Change from Baseline in Rasch-built Overall Disability Scale (R-ODS) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Délai: Baseline and Month 18
|
The R-ODS is a patient-reported measure of level of disability on a scale of 0-48, with 0 being the worst and 48 the best (no limitations); scores are based on activities of daily living and social participation. An increase in R-ODS from baseline suggests improvement in disability, and a decrease from baseline suggests worsening of disability. |
Baseline and Month 18
|
|
Change from Baseline in Timed 10-meter Walk Test (10-MWT) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Délai: Baseline and Month 18
|
The timed 10-MWT is a measure of ambulatory ability and measures the time (in seconds) that it takes a participant to walk 10 meters (gait speed). An increase in gait speed from baseline represents improvement, and a decrease from baseline represents worsening. |
Baseline and Month 18
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Les enquêteurs
Les enquêteurs
- Directeur d'études: Medical Director, Alnylam Pharmaceuticals
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- ALN-TTRSC04-004
- 2025-522544-40-00 (Ctis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Phase 2-4 trials:
Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU.
Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, a planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more.
Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .